The AI buying guide for Business Development & Licensing (BD&L) executives

Evaluate & choose AI solutions to achieve real results

Your biopharma BD&L teams are under unprecedented pressure to deliver results. They must quickly identify, thoroughly investigate, and reduce risk on new opportunities while sifting through increasingly larger volumes of global assets. 

AI promises to solve key pain points throughout search, eval, and diligence. However, it can be a huge challenge to choose an AI solution with the exact capabilities your team requires. The wrong choice could cost your organization its next blockbuster asset.

Join us for this educational session on September 24 at 1 PM ET, where we will walk through a practical, executive-level framework to evaluate AI solutions for BD&L teams. You’ll learn:

• Why adoption of AI for search and eval is accelerating and the risks of waiting
• How to decide your path to AI (build, buy, or bespoke)
• The different types and tradeoffs of AI solutions
• Key AI solution selection criteria and considerations

The results you can achieve with an agentic AI, biopharma-based solution compared to traditional methods, including 8x faster asset diligence, 75% reduction in subject-matter workload, and 50% increase in asset identification.

Whether you are actively evaluating vendors or just starting to explore AI for your BD&L workflows, you will leave with a clear roadmap for making an informed, ROI-driven choice.